Gelonghui, January 9丨Bluesword Intelligent Technology (688557.SH) stated on the interactive platform that the company currently has no projects or related Business for developing quadruped robotic dogs. For more information on the company's R&D situation, please refer to the regular reports disclosed on the Shanghai Exchange website.
- Headlines
- Bluesword Intelligent Technology (688557.SH): Currently, there are no projects or related business in the development of quadruped robotic dogs.
兰剑智能(688557.SH)：目前没有研发四足机器狗的项目及其相关业务
Bluesword Intelligent Technology (688557.SH): Currently, there are no projects or related business in the development of quadruped robotic dogs.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Latest
17:48
Ukrainian Prime Minister: Ukraine has received the first 3 billion euros of the Group of Seven's special revenue acceleration (ERA) loan from the European Union.
17:47
Fosun Pharma: Controlled subsidiary obtains approval for pharmaceutical clinical trials.
Shanghai Fosun Pharmaceutical-1.50%
17:44
TENCENT has conducted large-scale repurchases for four consecutive days! Today it spent another 1.5 billion Hong Kong dollars to buy back shares.
TENCENT-1.02%
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.